Literature DB >> 27307530

Gottron Papules and Gottron Sign with Ulceration: A Distinctive Cutaneous Feature in a Subset of Patients with Classic Dermatomyositis and Clinically Amyopathic Dermatomyositis.

Hua Cao1, Qunli Xia1, Meng Pan1, Xiaoqing Zhao1, Xia Li1, Ruofei Shi1, Min Zhou1, Xiaoyi Ding1, Masataka Kuwana1, Jie Zheng2.   

Abstract

OBJECTIVE: Gottron papules and Gottron sign are characteristic and possibly pathognomonic cutaneous features of classic dermatomyositis and clinically amyopathic dermatomyositis (DM/CADM). However, the Gottron papules/Gottron sign with cutaneous ulceration (ulcerative Gottron papules/Gottron sign) are less common. We aimed to clarify the clinical characteristics of patients with DM/CADM who have ulcerative Gottron papules/Gottron sign.
METHODS: Clinical features, laboratory findings, and prognosis of patients with DM/CADM who had Gottron papules/Gottron sign with or without ulceration were analyzed and compared.
RESULTS: Occurrences of acute interstitial pneumonia/subacute interstitial pneumonia (AIP/SIP) were significantly higher in patients with ulcerative Gottron papules/Gottron sign (19/26) versus patients with Gottron papules/Gottron sign without ulceration (2/66, p < 0.001). We also observed that the white blood cell counts (mean ± SD 4.2 ± 1.6 vs 6.9 ± 2.9; p < 0.001) and creatine kinase (CK) levels (198.0 ± 377.7 vs 1364.0 ± 2477.0; p = 0.019) were significantly lower, whereas the positive rate of antimelanoma differentiation-associated gene 5 antibody (anti-MDA5; 88.5% vs 6.1%, p < 0.001) and serum ferritin levels (665.2 ± 433.5 vs 256.2 ± 279.0, p < 0.001) were significantly higher in the patients with ulcerative Gottron papules/Gottron sign. Moreover, the cumulative survival rate of the group with ulcerative Gottron papules/Gottron sign was significantly lower (p < 0.001).
CONCLUSION: Patients with DM/CADM who have ulcerative Gottron papules/Gottron sign, positive anti-MDA5 antibody, and significantly lower baseline CK level are at increased risk of interstitial lung disease, especially AIP/SIP. A new designation for this subgroup of patients should be established to draw more attention to this clinical entity.

Entities:  

Keywords:  AMYOPATHIC DERMATOMYOSITIS; DERMATOMYOSITIS; INTERSTITIAL LUNG DISEASE; SKIN ULCER

Mesh:

Substances:

Year:  2016        PMID: 27307530     DOI: 10.3899/jrheum.160024

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  11 in total

1.  The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies.

Authors:  Shanshan Li; Yongpeng Ge; Hanbo Yang; Tao Wang; Xiaoxiao Zheng; Qinglin Peng; Xin Lu; Guochun Wang
Journal:  Clin Rheumatol       Date:  2019-03-12       Impact factor: 2.980

2.  A New Predictive Model for the Prognosis of MDA5+ DM-ILD.

Authors:  Qian Niu; Li-Qin Zhao; Wan-Li Ma; Liang Xiong; Xiao-Rong Wang; Xin-Liang He; Fan Yu
Journal:  Front Med (Lausanne)       Date:  2022-06-15

3.  Identification of Biomarkers Associated With CD4+ T-Cell Infiltration With Gene Coexpression Network in Dermatomyositis.

Authors:  Peng Huang; Li Tang; Lu Zhang; Yi Ren; Hong Peng; Yangyang Xiao; Jie Xu; Dingan Mao; Lingjuan Liu; Liqun Liu
Journal:  Front Immunol       Date:  2022-05-30       Impact factor: 8.786

Review 4.  Covert clues: the non-hallmark cutaneous manifestations of dermatomyositis.

Authors:  Rochelle L Castillo; Alisa N Femia
Journal:  Ann Transl Med       Date:  2021-03

Review 5.  Pathogenesis of Anti-melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis: A Concise Review With an Emphasis on Type I Interferon System.

Authors:  Huifang Hu; Hang Yang; Yi Liu; Bing Yan
Journal:  Front Med (Lausanne)       Date:  2022-01-24

6.  Anti-MDA5 Amyopathic Dermatomyositis-A Diagnostic and Therapeutic Challenge.

Authors:  Anca Bobirca; Cristina Alexandru; Anca Emanuela Musetescu; Florin Bobirca; Anca Teodora Florescu; Magdalena Constantin; Tiberiu Tebeica; Alesandra Florescu; Sebastian Isac; Mihai Bojinca; Ioan Ancuta
Journal:  Life (Basel)       Date:  2022-07-23

7.  MDA-5 dermatomyositis complicated by interstitial lung disease and cutaneous ulcers: successful treatment with corticosteroids, mycophenolate mofetil and intravenous immunoglobulin.

Authors:  Kelli Stager; Leanna Wise
Journal:  BMJ Case Rep       Date:  2020-09-30

8.  Deep Cutaneous Ulcers in Dermatomyositis.

Authors:  Takao Nagashima; Jun Nakamura; Masahiro Iwamoto; Seiji Minota
Journal:  Intern Med       Date:  2017-07-01       Impact factor: 1.271

Review 9.  Bench to bedside review of myositis autoantibodies.

Authors:  Boaz Palterer; Gianfranco Vitiello; Alessia Carraresi; Maria Grazia Giudizi; Daniele Cammelli; Paola Parronchi
Journal:  Clin Mol Allergy       Date:  2018-03-07

10.  Interstitial Lung Disease-Complicated Anti-MDA5 Antibody in Clinically Amyopathic Dermatomyositis Patients: Report of Two Cases With Distinct Clinical Features.

Authors:  Laurence Pacot; Jacques Pouchot; Nicolas De Prost; Marie Senant; Eric Tartour; Françoise Le Pimpec-Barthes; Dominique Israel-Biet; Marie-Agnes Dragon-Durey
Journal:  Front Med (Lausanne)       Date:  2020-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.